Department of Surgery, Division of Plastic and Reconstructive Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
Ann Surg Oncol. 2012 Mar;19(3):892-900. doi: 10.1245/s10434-011-1989-4. Epub 2011 Aug 16.
To describe the clinical outcomes of patients with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy and preoperative radiotherapy, followed by skin-sparing mastectomy (SSM) and immediate autologous breast reconstruction (IABR).
A retrospective review of 30 LABC patients who underwent SSM and IABR between 1997 to 2007 was performed. Data were drawn from patient records and the University of British Columbia (UBC) Breast Reconstruction and British Columbia Cancer Agency databases.
All 30 patients received neoadjuvant chemotherapy, preoperative radiotherapy, SSM, and IABR. Fifteen patients (50%) had stage IIIA disease, 13 (43%) stage IIIB, and 2 (6.7%) stage IIIC. Reconstruction types included the pedicled transverse rectus myocutaneous flap (n = 24), the latissimus dorsi flap (n = 5), and a combination of transverse rectus myocutaneous and latissimus dorsi flap (n = 1). The median follow-up was 3.51 years (range 1-9.4 years). Local complications included mastectomy flap necrosis (n = 3), partial flap necrosis (n = 1), fat necrosis (n = 1), seroma (n = 3), infection (n = 2), and flap fibrosis (n = 1). The incidence of donor site complications was 20%. Overall 5-year actuarial locoregional relapse-free, distant relapse-free, and disease-specific survival rates were 80, 65, and 68%, respectively. Excellent or good physician-rated aesthetic results were achieved in 66% of patients.
The UBC protocol avoids irradiation of the autologous breast reconstruction. Outcomes compare with findings from similar studies with respect to local recurrence, distant relapse, overall survival, and surgical complication rates. Neoadjuvant chemotherapy and preoperative radiotherapy in LABC patients desiring autologous breast reconstruction can be considered a safe option.
描述接受新辅助化疗和术前放疗、随后行保留皮肤的乳房切除术(SSM)和即刻自体乳房重建(IABR)的局部晚期乳腺癌(LABC)患者的临床结局。
对 1997 年至 2007 年间接受 SSM 和 IABR 的 30 例 LABC 患者进行回顾性研究。数据来自患者病历和不列颠哥伦比亚大学(UBC)乳房重建和不列颠哥伦比亚癌症机构数据库。
所有 30 例患者均接受新辅助化疗、术前放疗、SSM 和 IABR。15 例(50%)患者患有 IIIA 期疾病,13 例(43%)患有 IIIB 期疾病,2 例(6.7%)患有 IIIC 期疾病。重建类型包括带蒂横直肌肌皮瓣(n = 24)、背阔肌皮瓣(n = 5)和横直肌肌皮瓣与背阔肌皮瓣联合(n = 1)。中位随访时间为 3.51 年(范围 1-9.4 年)。局部并发症包括乳房切除术皮瓣坏死(n = 3)、部分皮瓣坏死(n = 1)、脂肪坏死(n = 1)、血清肿(n = 3)、感染(n = 2)和皮瓣纤维化(n = 1)。供区并发症发生率为 20%。总体 5 年局部无复发生存率、远处无复发生存率和疾病特异性生存率分别为 80%、65%和 68%。66%的患者获得了医生评价的良好或优秀的美学效果。
UBC 方案避免了对自体乳房重建的放疗。局部复发、远处复发、总体生存率和手术并发症发生率与类似研究结果相当。对于希望进行自体乳房重建的 LABC 患者,新辅助化疗和术前放疗可被视为一种安全选择。